MIPs are prepared using a proprietary imprinting process involving the self-assembly of binding monomers around a target to create a novel affinity reagent.
Monomers are then polymerised to generate a nanoMIP with a single binding site: a ‘synthetic’ antibody. Our proprietary technology includes a novel method to produce nanoMIPs which circumvents the drawbacks of traditional Molecularly Imprinted Polymer manufacturing methods. nanoMIPs have been created to small molecules, metabolites, peptides, proteins, viruses and more. Targets are not limited to those that elicit an immune response or toxicity; no animals are used in the manufacture of Molecular Imprinted Polymers.